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All nascent neoplasms probably elicit at least a weak immune reaction. However, the initial eﬀect of the weak immune reaction on
a nascent tumor is always stimulatory rather than inhibitory to tumor growth, assuming only that exposure to the tumor antigens
did not antedate the initiation of the neoplasm (as may occur in some virally induced tumors). This conclusion derives from the
observation that the relationship between the magnitude of an adaptive immune reaction and tumor growth is not linear but
varies such that while large quantities of antitumor immune reactants tend to inhibit tumor growth, smaller quantities of the same
reactantsare,forunknownreasons,stimulatory.Anyimmunereactionmustpresumablybesmallbeforeitcanbecomelarge;hence
theinitialreactiontotheﬁrstpresentationofatumorantigenmustalwaysbesmallandinthestimulatoryportionofthisnonlinear
relationship. In mouse-skin carcinogenesis experiments it was found that premalignant papillomas were variously immunogenic,
but that the carcinomas that arose in them were, presumably because of induced immune tolerance, nonimmunogenic in the
animal of origin.
1.Introduction
The immune surveillance hypothesis, championed in the
60s by Burnet [1] to explain why many cancers, although
part of the self, are nonetheless immunogenic, has had
a disputatious history. One of the earliest arguments in
favor of the surveillance hypothesis was the observation
that immunodepression increased the incidence of certain
human cancers, especially those of the skin and of the lymph
system [2]. However, Stutman, in a comprehensive survey,
could ﬁnd no evidence that immunodepression aﬀected
carcinogenesis [3]. More recently, Schreiber and Podack
have reopened the question by publishing an analysis of the
validity of the immune surveillance hypothesis in the case
of methylcholanthrene-induced carcinogenesis [4]. Their
conclusion was, in essence, that immunodepression often
increased tumor growth and/or incidence, thus supporting
the existence of anticancer immune surveillance.
2.TwoIllustrativeExperiments
T h el a t eD r .M a r cL a p p´ e and I published a paper apparently
showing the role of immune surveillance during chemically
induced skin carcinogenesis [5]. We based these studies
upon a system in which a suboncogenic dosage of 3-
methylcholanthrene (MCA) was applied as an “initiator” to
the backs of BALB/c mice. After a short interval, the initiated
skin was “promoted” by orthotopic transplantation to
syngeneic mice whose immune capacities had been modiﬁed
by various means; the transplanted skins were then observed
over time for the development of skin papillomas (paps)
and carcinomas. All carcinomas arose within previously
identiﬁed paps on the skin grafts and were easily identiﬁed
by gross examination [5]. Transplantation proved to be an
eﬃcient promoter and was used to avoid, as far as possible,
systemic immunodepressive eﬀects on the host animals by
the initiating MCA.2 Clinical and Developmental Immunology
Lapp´ e’s work suggested that the host’s immune capacity
can modify both the incidence and the duration of MCA-
induced skin paps, albeit primarily the duration. Most paps
ultimately regressed. At the time the work was performed, it
was assumed that the longer duration of paps and the higher
incidence of carcinomas in the immunodepressed animals,
in the Lapp´ e and similar experiments, were supportive of the
immune surveillance hypothesis [5].
Subsequently, another student of mine performed exper-
iments very similar to those of Lapp´ e, but with a slightly
diﬀerent objective [6]. The question asked by Andrews was
whether or not paps could regress in the complete absence
of immunity (or in as nearly complete absence as could
technically be obtained)? The experimental protocol was
modiﬁed as follows: as a further test of the eﬃcacy of the
imposed immunodepression, “promotion” was achieved by
transplanting the MCA-initiated skin to allogeneic rather
thantoisogenicrecipients.Priortotransplantation,thehosts
were immunodepressed by thymectomy and x-radiation
as well as by weekly injections of antilymphocyte serum.
Although in one experiment many animals became ill, in
most experiments survival appeared to be normal, and the
allografts survived indeﬁnitely. By several diﬀerent addi-
tional tests, no residual immune capability was detectable
[6].
Andrews’ data showed that, in the absence of detectable
immune capacity in the hosts, MCA-induced papillomas
occurred and persisted for varying lengths of time before
most of them regressed; to our surprise, none progressed to
carcinoma [6].
The Lapp´ e and Andrews data seem discordant in that
Lapp´ e found that a moderate immunodepression increased
thecarcinomaincidence;Andrews,incontrast,foundthatan
even greater degree of immunodepression vastly reduced the
incidence of carcinomas. How can the Lapp´ e and Andrews’
data sets be reconciled?
3. The Hormetic Natureof the Immune
Response Curve
The key to this seeming discrepancy probably lies in the fact
that the two sets of experiments were done at very diﬀerent
points on the titration curve of the immune response. This
titration curve was almost certainly not linear. In 1972, I
showed that the eﬀect of quantitative variations of adaptive
immunity on tumor growth followed an immune response
curve (IRC) suggestive of hormesis [7] (see Figure 1).
This same basic observation has been made many times
andinmanydiﬀerentexperimentalsystems;lowquantitative
levels of immunity tend to stimulate both carcinogenesis
and the growths of tumor implants while larger amounts of
apparently the same immunological reactants are inhibitory
to neoplastic growths [8]. Thus, when a tumor grows
better, either faster or in greater frequency as a result of
immunodepression, one often cannot be sure whether the
result was caused by a lessened inhibition or by a greater
stimulation of the growth of the target neoplasm. The

















































Figure 1: Immune response curve (IRC). Idealized curve derived
from data in [7] showing the hormetic shape of the curve titrating
the quantity of immune reactants against the eﬀect on tumor
growth. Letters and numerals are arbitrary aids to discussion.
unknowable; knowing where on the nonlinear quantitative
scale of immune eﬀects the reaction actually resides.
Since no malignancies occurred in the near absence of
an immune reaction, the work of Andrews suggests strongly
that, in the system he explored, a greater stimulatory eﬀect
of immunity would have been helpful and perhaps even
necessary for papilloma progression to carcinoma; this is
the expected result of immune reactions falling far to the
left of “c” on the IRC in Figure 1. Also, it may perhaps
be possible to postulate that papilloma regression may have
been, at least in part, a consequence of insuﬃcient immune
stimulation It thus becomes reasonable to ask whether the
longer-lasting paps in the immunodepressed mice in the
Lapp´ eworkwerealsoaconsequenceofgreaterimmunestim-
ulation rather than a relative paucity of immune inhibition.
Lapp´ e deﬁnitely showed that immunodepression increased
the incidence of MCA-induced skin carcinomas while an
artiﬁcially increased immune capacity was associated with
fewer carcinomas [5]; thus, most of the Lapp´ ep a p sm u s t
have occurred in an area of the titration curve where a
lessened or an increased host immune capacity would result
in greater or lesser papilloma incidence respectively, that
is, somewhere to the right of “d” on the IRC (Figure 1).
Whether the paps fell to the right or to the left of “e”, that
is, whether the immunity to the paps was in the stimulatory
or the inhibitory range, remains unknown by this analysis,
but I will argue subsequently that it was probably in the
stimulatory portion of the curve.
One caveat must be noted at this point. As the immune
reaction is presently understood, the fact that Andrews used
allogeneictransplantationfor“promotion”whileLapp´ eused
syngeneic should not have been a signiﬁcant diﬀerence;
however, if there was a diﬀerence in the promotional eﬀects
ofthetwoprocedures,thepapillomasinthetwoexperiments
might not have been exactly comparable.
In the Lapp´ e experiment, it is apparent that the papil-
lomas were immunogenic in as much as their longevity was
markedly inﬂuenced by the imposed alteration of the hosts’
immune capacities. However, the immune capacities of the
host animals had little or no inﬂuence upon the growthsClinical and Developmental Immunology 3
of the carcinomas that resulted from the progression of
the immunogenic paps; as already noted, a quite constant
percentage of surviving paps became carcinomatous in
subsequent successive intervals of observation. It therefore
follows that in the Lapp´ e experiments, overt tumor progres-
sion coincided with the development of a marked degree of
immunological tolerance to the tumor antigens.
Itwouldseemlogicalthatanynewlyengenderedimmune
reaction begins small and only with time might become
suﬃciently robust to inhibit, rather than stimulate, tumor
growth; the immune reaction to any tumor antigen must,
given the essential correctness of the IRC, begin at the
extreme left end of that curve; thus the initial immune
reaction to newly presented tumor antigens is necessarily
always stimulatory.
The prolongation of the longevity of paps in the Lapp´ e
immunodepressed mice, and in all similar oncogenesis
experiments in which immunodepression results in more
tumor growth, may often be caused by immune stimulation
of the tumors rather than by the reduction of an assumed
tumor inhibition. Whenever immunodepression results in
fewer tumors and/or less tumor growth, the system, with
the immunodepression being absent, was probably near or
to the left of “c” and was moved even further to the left
by the reduced immune reaction; in contrast, whenever
immunodepression results in more tumors and/or more
tumor growth, the system, with the immunodepression
beingabsent,wouldhavefallensomewheretotherightof“c”
and be moved further toward “c” by the immunodepression.
The fact that the initial immune reaction to a tumor is
necessarily stimulatory to tumor growth does not imply
that the reaction might not, in some cases, eventually grow
to inhibitory levels (to the right of “e”) and, in such
cases, immunodepression would also result in higher tumor
incidences.
Stutman, in his already mentioned survey concerning
the lack of eﬀect on oncogenesis by immunodepression [3],
could ﬁnd no evidence of either immune surveillance or
of immune stimulation. I suggest that this result would be
expected if most carcinogenesis experiments actually fall
near “c” on the ICR; in some cases, oncogenesis would
be relatively inhibited and in others relatively stimulated
by further immunodepression of the already weak immune
response to the incipient tumor. In some cases, variation
around “c” among the individual tumor antigenicites might
wellresultinexamplesofbothrelativeinhibitionandrelative
stimulation of tumor growth by immunodepression within a
single experiment, thus producing a null eﬀect.
4. Tumor Antigens
Cancers evoked by chemical carcinogens and by onco-
genic viruses usually contain strong antigens that can be
demonstrated by the resistance to the growth of the tumors
when tested by transplantation to speciﬁcally immunized
syngeneic animals. However, these tumor antigens are very
diﬃcult to demonstrate by tests done in the animal of origin
[9].
In the case of the virally induced tumors, the usual
explanation for the diﬃculty in immunization of the animal
oforiginisthatsuchanimalsarepartiallytoleranttothevirus
whichformsanintrinsicpartofthetumorantigen.Tolerance
to the carcinogen is apparently not a factor in chemically
induced tumors, but the diﬃculty of immunizing the animal
of origin is, at least in part, thought to be caused by the well-
known immunodepressive activity of the carcinogen [10].
In contrast to the chemically and virally induced tumors,
sporadic tumors of unknown etiology in rodents, are usually
weakly, if not completely, nonimmunogenic by similar tests.
That they may indeed possess a slight immunogenicity is
suggested by the fact that in the oft cited paper by Hewitt
[11], 7 of 7 such tumors, tested by speciﬁc immunization,
showed a small increased growth apparently produced by the
immunization procedure [11].
Yet another situation in which the immunogenicity of
a tumor is relatively diﬃcult to demonstrate results from
the “sneaking through” phenomenon: a tiny amount of
transplanted antigenic tumor often grows well when a larger
inoculumwouldhavefailed[12].Itmaybeimportanttonote
that the animal of origin of any tumor has perforce been
exposed to what may be an analogous phenomenon. Each
tumor originates from a single or at best a tiny clump of cells
and thus must “sneak through” in that original animal. This
manner of exposure to antigen apparently produces some
form of partial tolerance to the tumor antigens, while the
tumor remains demonstrably immunogenic if tested in a
diﬀerent animal. The prevalence of at least a partial tolerance
to the tumor’s antigens in the animal of origin seems to
further assure that tumors will usually exhibit in that animal
only a weak immunogenicity that will thus usually lie in the
stimulatory part of the IRC.
5. ClinicalImplications
Parenthetically, the Lapp´ e data suggest that the immune
reaction worked almost entirely upon the longevity of the
papillomas; the number of paps becoming malignant was a
function of the number of paps remaining at risk and was a
constant proportion of those paps surviving into successive
time intervals [5]. Kreider et al. also found, in somewhat
analogous experiments with papilloma induction in rats by
the Shope papilloma virus, that altering the host’s immune
capacities altered primarily the longevity, not the incidence,
of paps [13]. This curious result is overtly similar to the
appearance of mammary tumors in females of Dr H.B.
Andervont’s milk-agent-infected C3H mouse colony; after
the ninth month mammary tumors appeared, at successive
monthly time intervals, in a constant proportion of the
females remaining at risk [14]. Also, other data have shown
that, while the annual cancer incidence of each individual
varies depending upon the number of years of exposure
to tobacco smoke, in the ex-smoker, the risk of cancer
tends to become a constant in each successive year after
he or she stopped smoking [15–17]. Seemingly, it may be
a common property of many types of carcinoma to arise,
in each successive time interval after the initiating events,4 Clinical and Developmental Immunology
in a constant small proportion of those benign lesions that
have not yet regressed and are still available for malignant
progression.
The existence of tumor stimulation rather than surveil-
lance following tumor initiation may help to explain some
otherwiseperplexingobservations.Oneofthemostdramatic
of these, consistent with the hormetic shape of the IRC
(Figure 1) and the immune stimulation hypothesis, is the
behaviorofKaposi’ssarcoma.ThislesioniscommoninAIDS
patients, but it often “ﬂares” as the immune mechanism
recovers during therapy [18]. The most likely interpretation
appears to be that the tumor grows best (is stimulated) when
the patient’s immune capacity is low, but not too low. If the
sarcomas were to grow better in AIDS patients because of a
lack of immune inhibition, they would not be expected to
ﬂare,astheydoduring atransitoryperiod ofpartial immune
recovery.
Further clinical evidence that may support the idea
of immune stimulation of tumor growth in the primary
tumor bearer has recently been presented by Roscigno et
al.: removal of tumor-negative lymph nodes, in a very large
cohort (412 patients) with upper-tract urothelial carcino-
mas, signiﬁcantly improved the prognosis [19]. This ﬁnding
suggests that this system lies to the left of “c” on the IRC and
may have resulted from the removal of tumor-stimulatory
lymphoid elements rather than, or in addition to, the
more conventional explanation that undetected microscopic
metastases were removed along with the lymph nodes.
A large number of other correlates of the immune
stimulationhypothesishavebeendiscussedelsewhere[8,20],
among which is the observation that immunodepression
has been reported to reduce rather than increase the
incidencesofbothhumanbreast[21]andr ectal[22]canc ers.
Immune surveillance has no explanation for this behavior,
but according to the immune stimulation hypothesis, these
tumors are probably so weakly immunogenic that they
usually fall to the left of “c”. In that stimulatory region of
the IRC, further reduction of the immune reaction would
lead to less tumor stimulation. Thus, as may be suggested
by both human breast and rectal carcinoma incidences, a
reduced immune capability may sometimes be less, rather
than more, conducive to oncogenesis. The fact remains that
the incidences of most human tumors, probably as a result of
tolerance as well as of a relative paucity of antigenicity, have




The mechanism of immunostimulation is still, I think,
undetermined. Perhaps the simplest way to think of the
whole phenomenon of hormesis may be to recognize the
likelihood that every living tissue has probably evolved to
be capable of a variety of compensatory defenses against
any likely toxin (the immune response in the present case)
and that such anti-toxic devices may often overcompensate
to a small extent (hormesis is typically a phenomenon of
small extent [24]). The fact that some human cancers are
apparently helped to grow by immunodepression (skin and
lymphoid tumors) while others (breast and rectal tumors)
are perhaps relatively inhibited suggests the hypothesis
that most oncogenesis probably occurs on the IRC either
immediatelytotherightortotheleftof“c”inthestimulatory
part of the IRC curve.
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